Highlights

  • Acrux (ASX:ACR) reported FY26 revenue of AUD 6.596 million, an increase of 46%.
  • FY26 net loss narrowed to AUD 604,000, compared with approximately AUD 5.945 million a year earlier.
  • September-quarter net operating cash inflow was AUD 226,000, including an AUD 1.977 million tax rebate.
  • The FDA clarified requirements for two Phase III trials of Acrux’s Female Testosterone MDTS.

Acrux Limited develops and commercialises medicines applied through the skin, including topical pharmaceutical gels, creams and sprays, with licensed products serving international markets, particularly the United States. At the time of writing on 23 October 2026, Acrux (ASX:ACR) was quoted at AUD 0.010, down 9.09% for the trading session. Its current disclosures focus on FY26 financial results, September-quarter liquidity and the regulatory development programme for Female Testosterone MDTS.

Company Business

Acrux (ASX:ACR) operates in specialty pharmaceuticals, using its transdermal formulation and delivery capabilities to develop medicines administered through the skin. The company has historically commercialised generic topical products through licensing arrangements with external partners. Its established portfolio includes formulations such as dapsone gels and nitroglycerin ointment distributed in the United States. Royalties and profit-sharing arrangements provide income from commercialised products.

During FY26, the business shifted its principal development focus to Female Testosterone Metered Dose Transdermal System, or MDTS. The treatment under development is intended for postmenopausal women with hypoactive sexual desire disorder, a condition involving persistently low sexual desire. Acrux plans to advance the programme through a co-development model involving clinical, manufacturing and commercial partners.

Recent Development

In October 2026, Acrux (ASX:ACR) reported formal feedback from the US Food and Drug Administration following an end-of-Phase II meeting. The regulator indicated that two adequately controlled 24-week Phase III studies could support efficacy assessment for the proposed indication. An additional 28 weeks of data, bringing safety evaluation to 52 weeks, would inform longer-term treatment safety. Final trial protocols remain under development.

The FDA also indicated that the new formulation and proposed trials meet eligibility requirements for Acrux to apply for three years of data exclusivity upon regulatory submission. Eligibility does not amount to approval or a guarantee that exclusivity will be granted. The company continues discussions with prospective co-development partners to share the demands of later-stage clinical development.

In its September-quarter report issued on 19 October, the company outlined a reorganisation of its workforce following its decision to cease further development of its topical generic pipeline and external laboratory fee-for-service activities. Six redundancies implemented in July reduced employee numbers to 19. Acrux also confirmed receipt of the FY26 research and development tax incentive rebate during the quarter.

Financial Performance and Sector Context

For FY26, Acrux (ASX:ACR) reported total revenue of AUD 6.596 million, up 46% from the prior year. Its net loss declined to AUD 604,000 from approximately AUD 5.945 million in FY25. These statutory results reflect the company’s changing business mix, including monetisation of existing assets. The FY26 report recorded no dividend declared or paid.

The September 2026 quarter produced AUD 463,000 of customer receipts, including profit-share, royalty and laboratory-related income. The company reported AUD 226,000 in net operating cash inflow, supported by an AUD 1.977 million research and development tax incentive receipt. The positive quarterly cash-flow figure therefore should not be interpreted as evidence that recurring operations alone generated a surplus.

Quarterly cash payments included AUD 255,000 for research and development, AUD 1.344 million for staff and AUD 478,000 for administration and corporate activities. Staff payments included AUD 329,000 associated with six redundancies. Financing cash flows were negative AUD 531,000, with repayment of earlier tax-rebate advances contributing to cash outflows.

At 30 September 2026, Acrux held AUD 1.396 million of cash and cash equivalents, against AUD 1.705 million three months earlier, and reported AUD 399,000 in unused financing facilities. The company indicated that it was working on transactions to support the planned clinical programme. Pharmaceutical development remains dependent on trial results, regulatory assessment and access to funding.

Risks to Consider

Acrux (ASX:ACR) faces the costs and uncertainties of late-stage clinical trials, including recruiting participants, demonstrating treatment efficacy and establishing chronic-use safety. Its planned co-development arrangements remain subject to negotiations and execution. Limited cash resources relative to the anticipated scale of Phase III activity increase the importance of securing additional funding. Existing product royalties may fluctuate with licensee sales, while regulatory authorisation and any data exclusivity remain contingent on future decisions.

What to Watch Next

For Acrux (ASX:ACR), the next identifiable milestones include final Phase III protocols, progress on a co-development agreement, manufacturing and safety-study preparations, and further communication with US regulators. Subsequent cash-flow statements will also show how the expense reduction programme, royalty receipts and clinical spending affect liquidity. The company’s stated goal is to progress Female Testosterone MDTS through clinical development before any application for marketing approval.

Key Insights

Acrux’s FY26 reporting recorded higher revenue and a smaller statutory loss, while the September quarter showed positive operating cash flow largely due to a tax incentive rebate. The FDA has clarified key Phase III study requirements, but substantial development steps remain. For Acrux (ASX:ACR), financing arrangements, clinical trial execution and ongoing portfolio income are the central measurable items in forthcoming announcements.